11.5. non-invasive male infertility management. 11.5.1. empirical treatments 11.5.1.1. life-style environmental lifestyle factors may contribute male infertility acting additively susceptible genetic background . hence, lifestyle improvement positive effect sperm parameters. includes: weight loss: non-controlled studies suggested weight loss result improved sperm parameters . however, data derived rcts conflicting. meta-analysis 28 cohort studies 1,022 patients, documented bariatric surgery improve sperm quality function morbidly obese men . data art outcomes lacking. furthermore weight loss improve obesity-related secondary hypogonadism, may result better outcomes couples seeking medical care infertility .physical activity: meta-analysis documented moderate-intensity (20–40 metabolic equivalents [mets]/week) even high-intensity (40–80 mets-h/week) recreational physical activity result better semen parameters . moreover, physical activity might improve hormonal profile .smoking: data derived large meta-analysis 20 studies 5,865 participants showed negative association smoking sperm parameters . alcohol consumption: data derived recent meta-analysis including 15 cross-sectional studies 16,395 men suggested moderate alcohol adversely affect semen parameters, whereas high alcohol intake detrimental effect male fertility heavy chronic alcohol consumption (defined > 2 drinks/day ) reduce testosterone levels . 11.5.1.2. antioxidant treatment oxidative stress considered important contributing factors pathogenesis idiopathic infertility. reactive oxygen species, final products os, impair sperm function acting several levels, including plasma membrane lipid peroxidation, affect sperm motility, acrosome reaction chromatin maturation leading increased sdf . accordingly, seminal levels ros negatively associated art outcomes . despite this, evidence role antioxidant therapy male infertility still conflicting. cochrane systematic review meta-analysis including 34 rcts 2,876 couples using various antioxidant compounds, concluded antioxidant therapy positive impact live-birth pregnancy rates sub-fertile couples undergoing art cycles . similar results also reported meta-analysis including 61 studies 6,264 infertile men, aged 18-65 years . however, quality reported studies poor. males, antioxidants, infertility (moxi) trial found antioxidants improve semen parameters dna integrity compared placebo among infertile men male factor infertility. moreover, cumulative live-birth rate differ 6 months antioxidant placebo groups (15% vs. 24%) . clear conclusions possible regarding specific antioxidants use and/or therapeutic regimes improving sperm parameters pregnancy rate . 11.5.1.3. selective oestrogen receptor modulators selective oestrogen receptor modulators (serms) block oestrogen receptors level hypothalamus, results stimulation gnrh secretion, leading increase pituitary gonadotropin release stimulation spermatogenesis . meta-analysed data derived eleven rcts showed serms significantly increased pregnancy rate, sperm hormonal parameters . similar results confirmed latest updated meta-analysis sixteen studies . however, previous sr failed find association serms pregnancy rate . recognised quality papers considered low studies placebo-controlled. conclusion, although positive results relating use serms men idiopathic infertility reported, conclusive recommendations drawn due poor quality available evidence. furthermore, complications use serms under-reported. 11.5.1.4. aromatase inhibitors aromatase, cytochrome p450 enzyme, present testes, prostate, brain, bone, adipose tissue men; converts testosterone androstenedione oestradiol oestrone, respectively. oestradiol negatively feeds back hypothalamus pituitary reduce gonadotropic secretions, ultimately affecting spermatogenesis. context, aromatase inhibitors (ais) may decrease oestrogen production reversibly inhibiting cytochrome p450 isoenzymes 2a6 2c19 aromatase enzyme complex inhibiting negative feedback oestrogen hypothalamus resulting stronger gnrh pulses stimulate pituitary increase production fsh [1828-1831]. aromatase activity associated male infertility characterised testicular dysfunction low serum testosterone and/or testosterone oestradiol ratio. context, ais reported increase endogenous testosterone production improve spermatogenesis setting infertility off-label option treatment . either steroidal (testolactone) non-steroidal (anastrozole letrozole) ais significantly improve hormonal semen parameters infertile men, safe tolerability profile, although prospective rcts necessary better define efficacy medications clinical setting . 11.5.2. summary evidence recommendation non-invasive male infertility management summary evidencelein infertile men life style factors including obesity, low physical activity, smoking high alcohol intake associated decreased sperm quality.2ain men idiopathic oligo-astheno-teratozoospermia, life-style changes including weight loss increased physical activity, smoking cessation alcohol intake reduction may improve sperm quality chances conception.2ano conclusive data available regarding beneficial treatment antioxidants men idiopathic infertility, although may improve semen parameters.1bno conclusive data available regarding use selective oestrogen receptor modulators (serms) men idiopathic infertility.1bno conclusive data available regarding use steroidal (testolactone) nonsteroidal (anastrozole letrozole) aromatase inhibitors men idiopathic infertility.1b recommendationsstrength ratinginform infertile men detrimental effects obesity, low physical activity, smoking high alcohol intake sperm quality testosterone levels. therefore, advise infertile men improve life style factors improve chances conception.strongdo routinely treat patients idiopathic infertility antioxidants, selective oestrogen receptor modulators (serms) aromatase inhibitors (ais).weak 11.5.3. hormonal therapy 11.5.3.1. secondary hypogonadism (a brief discussion pre-pubertal-onset found appendix 12, online supplementary evidence). post-pubertal onset: human chorionic gonadotrophin (hcg) alone usually required first stimulate spermatogenesis. starting dose 250 iu hcg twice weekly suggested, normal testosterone levels reached, hcg doses may increased 2,000 iu twice weekly. again, semen analysis performed every three months assess response, unless conception taken place. failure stimulation spermatogenesis, fsh added (75 iu three times per week, increasing 150 iu three times per week indicated). similarly, combination therapy fsh hcg administered beginning treatment, promoting better outcomes men hh . difference outcomes observed urinary-derived, highly purified fsh compared recombinant fsh . greater baseline testicular volume good prognostic indicator response gonadotrophin treatment previous testosterone therapy negative impact gonadotropin treatment outcomes men hypogonadotropic hypogonadism . however, observation subsequently refuted meta-analysis confirm real negative role testosterone therapy terms future fertility specific setting . 11.5.3.1.1. secondary hypogonadism due hyperprolactinemia presence hyperprolactinaemia, causing suppression gonadotrophins resulting sub-fertility treatment independent aetiology (including pituitary adenoma) dopamine agonist therapy withdrawal drug causes condition. dopamine agonists used include bromocriptine, cabergoline quinagolide. 11.5.3.2. primary hypogonadism substantial evidence gonadotrophin therapy beneficial effect presence classical testicular failure. likewise, data support use hormonal treatments (including serms ais) case primary hypogonadism improve spermatogenesis . 11.5.3.3. idiopathic male factor infertility evidence fsh treatment increases sperm parameters idiopathic oligozoospermic men fsh levels within normal range (generally 1.5 – 8 miu/ml). also reported fsh may improve sdf rates well ameliorating amh inhibin levels [1836-1839]. high-dose fsh therapy effective achieving testicular response lower doses . cochrane review including six rcts 456 participants, different treatment protocols follow-up periods concluded fsh treatment resulted higher live-birth pregnancy rates compared placebo treatment. however, significant difference among groups observed icsi iui considered . meta-analysis including 15 trials > 1,200 patients, similar findings fsh treatment observed terms spontaneous pregnancies pregnancies art . study showed azoospermic men undergoing tese-icsi improved srrs higher pregnancy fertilisation rates men treated fsh compared untreated men . men noa, combination hcg/fsh therapy shown increase srr one study . human chorionic gonadotrophin alone prior tese noa found benefit srrs . overall evidence use hormone therapy prior ssr limited treatment confined clinical trials used routinely clinical practice. 11.5.3.4. anabolic steroid abuse oligospermia azoospermia result anabolic abuse treated initially withdrawal anabolic steroid. common indication treating disorder; management based case reports clinical experience. usually, adequate sperm numbers quality improve six twelve-month period cessation. interval condition persists, hcg without combination fsh alternative clomiphene used stimulate spermatogenesis . 11.5.3.5. summary evidence recommendations treatment male infertility hormonal therapy summary evidencelefollicle stimulating hormone (fsh) promotes spermatogenesis testicular growth puberty. human chorionic gonadotropin (hcg) acts like luteinizing hormone (lh) used stimulate intratesticular testosterone production spermatogenesis men hypopituitarism puberty.2bprepubertal secondary hypogonadism requires association fsh hcg pulsatile gnrh, even use limited difficult administration.1bsecondary hypogonadism adults effectively treated subcutaneous hcg fsh.2bthe use gnrh therapy expensive offer advantages compared gonadotropins treatment hypogonadotropic hypogonadism.3in postpubertal forms secondary hypogonadism, sequential use hcg fsh combination beginning options.1btesticular volume one main predictors response gonadotropin therapy men hypogonadotropic hypogonadism.2adopamine agonists used treat hyperprolactinaemia.2afsh therapy (any formulation) associated improvement sperm quality increased spontaneous assisted pregnancy rates idiopathic infertile males.2ano conclusive recommendations given use high-dose fsh men idiopathic infertility prior (m)tese therefore cannot routinely advocated.2atestosterone therapy contraindicated infertile men.1a recommendationsstrength ratinginduce spermatogenesis men congenital acquired hypogonadotropic hypogonadism wish conceive effective drug therapy (hcg; human menopausal gonadotropins; recombinant fsh; highly purified fsh).stronguse fsh treatment men idiopathic oligozoospermia fsh values within normal range, ameliorate spermatogenesis outcomes.weakdo treat idiopathic infertility high dose fsh.weakdo start hormonal stimulation prior tese men non-obstructive azoospermia (noa) outside clinical trials.weakdo use testosterone therapy treatment male infertility.strongprovide testosterone therapy symptomatic patients primary secondary hypogonadism considering parenthood.strongoffer dopamine agonist therapy men hyperprolactinemia improve sperm quality.weakwithdraw anabolic steroids infertile men six twelve months month considering treatment selective oestrogen receptor modulators (serms) gonadotrophin therapy induce spermatogenesis.weak